Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...

Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

The offering is entirely comprised of shares offered by Metsera, which could signal that existing investors are not participating in the IPO, potentially raising concerns about their confidence in ...

In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 ...